Low
₹147.00
High
₹153.10
| Previous Close | ₹147.80 |
|---|---|
| Day's Range | ₹147.00 - ₹153.10 |
| Open | ₹148.00 |
| 52 Week Range | ₹59.31 - ₹159.81 |
| Volume | 1,36,901 |
| Market Cap | ₹0.00 |
| Previous Close | ₹147.95 |
|---|---|
| Day's Range | ₹146.55 - ₹151.60 |
| Open | ₹147.90 |
| 52 Week Range | ₹59.72 - ₹160.10 |
| Volume | 6,013 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 205.09 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 383.15 |
| TTM EPS (₹) | 0.39 |
| P/E Ratio | 54.87 |
| Book Value(₹) | 2.72 |
| PAT Margin (%) | 1.56 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 5.47 |
| Trade Value ( ₹ in Lacs) | 8.97 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 383.15 |
| TTM EPS (₹) | 0.39 |
| P/E Ratio | 54.87 |
| Book Value(₹) | 2.72 |
| PAT Margin (%) | 1.56 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 5.47 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 883.94 | 3756.36 |
| Expenses | N/A | N/A |
| PBT | 2.28 | 176.12 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1.16 | 117.44 |
| Founded | 1984 |
|---|---|
| Managing Director | Anwar Siraj Daud |
| NSE Symbol | ZIMLAB |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,52,298.64 | 1,885.10 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,97,324.81 | 11,200.00 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,78,727.25 | 4,698.80 | 3,672.30 - 3,672.30 |
| Apollo Hospitals Enterprise Ltd. | 1,32,138.82 | 9,190.05 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,29,508.26 | 737.00 | 0.00 - 0.00 |
| Laurus Labs Ltd. | 1,24,001.65 | 2,295.00 | 917.95 - 917.95 |
| Zydus Lifesciences Ltd. | 1,19,206.70 | 1,195.05 | 835.50 - 835.50 |
| Dr. Reddy's Laboratories Ltd. | 1,16,144.51 | 1,390.50 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,14,312.12 | 1,414.95 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,09,880.22 | 2,660.00 | 1,909.70 - 1,909.70 |
No Records Found
With reference to the disclosure made by the Company on 11th February, 2026 regarding incorporation of a wholly owned subsidiary of the Company in Chile and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’), Zim Laboratories has informed that the Wholly Owned Subsidiary has been incorporated in the name of ‘ZIM Laboratories SpA’ in Santiago, Republic of Chile. The details required under Regulation 30 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, is also enclosed as Annexure- I.
In continuation to earlier letter Ref. No.P-66/2026-27/55 dated 16th November, 2026 respectively, 3B BlackBio Dx has informed that the Company interacted one to one with Fortuna Asset Managers LLP, Delhi on Saturday, 21th November, 2026 at 12:00 hrs India Time. The meeting concluded at 13:00 hrs India Time. The information which is already available in public domain was discussed and no unpublished price sensitive information pertaining to the company was shared with the investor. During this investor meeting, the company reiterated the information shared by it through Investor Presentation of Q2-FY27, which was earlier intimated to the Stock Exchanges vide Ref. No.P66/2026-27/53 dated 13th November, 2026. The company has enclosed the web link of the presentation placed before investors after the declaration of the financial results for the quarter and half year ended 30-09-2026 and the above-mentioned investor.
Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and in accordance with the SEBI Circular HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated 30th January 2026, Chennai Meenakshi Multispeciality Hospital has informed that it enclosed the copies of the newspaper advertisement published for the Equity Shareholders of the Company regarding the Special Window for Transfer and Dematerialisation of Physical Securities. The said advertisement was published in Financial Express & Makkal Kural Newspaper on Saturday, 19th November 2026.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Zim Laboratories Ltd. is ₹147.80 as of 2026-11-20.
The market capitalisation of Zim Laboratories Ltd. is ₹793.88 as of 2026-11-20.
The 1-year return of Zim Laboratories Ltd. is 74.39% as of 2026-11-20.
The P/E ratio of Zim Laboratories Ltd. is 54.87 as of 2026-11-21.
The 52-week high and low of Zim Laboratories Ltd. are ₹159.81 and ₹59.31, respectively, as of 2026-11-20.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.